ANIP vs PODD: fair value comparison
ANI Pharmaceuticals, Inc. and Insulet Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PODD currently sits closer to the top of our discount ranking.
| ANIP | PODD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $71.92 | $131.96 |
| 12-month range | $71.92–$94.06 | $148.13–$318.77 |
| Sector rank | #11 of 113 Healthcare | #2 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ANIP fair value analysis · PODD fair value analysis